1999
DOI: 10.1001/archderm.135.5.540
|View full text |Cite
|
Sign up to set email alerts
|

Turbo-PUVA: Dihydroxyacetone-Enhanced Photochemotherapy for Psoriasis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
21
0

Year Published

2000
2000
2012
2012

Publication Types

Select...
5
3
1

Relationship

0
9

Authors

Journals

citations
Cited by 31 publications
(22 citation statements)
references
References 13 publications
1
21
0
Order By: Relevance
“…23 Dihydroxyacetone, an isomer of glyceraldehyde, is present in most ''sunless'' tanning products, forming a brown pigment that simulates a suntan by the Maillard polymerization reaction. 28 The toxicity of any drug depends on its dose. Our study showed mild reversible side effects of the glyceraldehyde treatment in the peripheral cornea and the extraocular muscles, whereas the retina was unaffected.…”
Section: Discussionmentioning
confidence: 99%
“…23 Dihydroxyacetone, an isomer of glyceraldehyde, is present in most ''sunless'' tanning products, forming a brown pigment that simulates a suntan by the Maillard polymerization reaction. 28 The toxicity of any drug depends on its dose. Our study showed mild reversible side effects of the glyceraldehyde treatment in the peripheral cornea and the extraocular muscles, whereas the retina was unaffected.…”
Section: Discussionmentioning
confidence: 99%
“…There are no specific guidelines on the use of phototherapy while on DHA camouflage. Interestingly though, in a study by Taylor et al, [30] in 30 psoriatic patients on PUVA treatment, it was suggested that protection of uninvolved skin by DHA during PUVA treatment allows higher UV-A exposures to be tolerated, demonstrates faster clearing and requires fewer treatments to clear psoriasis. This could probably be extrapolated to the use of PUVA in vitiligo too.…”
Section: Kaliyadan and Kumarmentioning
confidence: 99%
“…It appears to be useful for the treatment of age-related macular generation and choroidal melanoma (42). BPD-PDT also has been tested for treatment of atherosclerotic plaques (43) and psoriasis (44,45 (48), and mono-L-aspartyl chlorin e6 (NPe6; l abs @ 664 nm) has recently entered clinical trials for superficial malignancies of the skin and nasopharynx (49).…”
Section: Photosensitizers and Clinical Trialsmentioning
confidence: 99%